1. Home
  2. BNGO vs NXL Comparison

BNGO vs NXL Comparison

Compare BNGO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNGO
  • NXL
  • Stock Information
  • Founded
  • BNGO 2003
  • NXL 2010
  • Country
  • BNGO United States
  • NXL United States
  • Employees
  • BNGO N/A
  • NXL N/A
  • Industry
  • BNGO Biotechnology: Laboratory Analytical Instruments
  • NXL Medical Specialities
  • Sector
  • BNGO Industrials
  • NXL Health Care
  • Exchange
  • BNGO Nasdaq
  • NXL Nasdaq
  • Market Cap
  • BNGO 24.3M
  • NXL 21.0M
  • IPO Year
  • BNGO 2018
  • NXL 2022
  • Fundamental
  • Price
  • BNGO $3.43
  • NXL $1.12
  • Analyst Decision
  • BNGO Buy
  • NXL Strong Buy
  • Analyst Count
  • BNGO 5
  • NXL 1
  • Target Price
  • BNGO $7.33
  • NXL $5.00
  • AVG Volume (30 Days)
  • BNGO 86.1K
  • NXL 116.3K
  • Earning Date
  • BNGO 08-06-2025
  • NXL 08-07-2025
  • Dividend Yield
  • BNGO N/A
  • NXL N/A
  • EPS Growth
  • BNGO N/A
  • NXL N/A
  • EPS
  • BNGO N/A
  • NXL N/A
  • Revenue
  • BNGO $28,464,000.00
  • NXL $131,065.00
  • Revenue This Year
  • BNGO N/A
  • NXL $79.59
  • Revenue Next Year
  • BNGO $15.54
  • NXL $334.65
  • P/E Ratio
  • BNGO N/A
  • NXL N/A
  • Revenue Growth
  • BNGO N/A
  • NXL N/A
  • 52 Week Low
  • BNGO $2.68
  • NXL $0.59
  • 52 Week High
  • BNGO $41.10
  • NXL $4.49
  • Technical
  • Relative Strength Index (RSI)
  • BNGO 49.89
  • NXL 54.25
  • Support Level
  • BNGO $3.33
  • NXL $0.97
  • Resistance Level
  • BNGO $3.47
  • NXL $1.08
  • Average True Range (ATR)
  • BNGO 0.11
  • NXL 0.08
  • MACD
  • BNGO 0.03
  • NXL 0.03
  • Stochastic Oscillator
  • BNGO 84.00
  • NXL 70.00

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: